The DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.
Promotion of Hepatocellular Carcinoma by the Intestinal Microbiota and TLR4
Open accessAbstract
Increased translocation of intestinal bacteria is a hallmark of chronic liver disease and contributes to hepatic inflammation and fibrosis. Here we tested the hypothesis that the intestinal microbiota and Toll-like receptors (TLRs) promote hepatocellular carcinoma (HCC), a long-term consequence of chronic liver injury, inflammation, and fibrosis. Hepatocarcinogenesis in chronically injured livers depended on the intestinal microbiota and TLR4 activation in non-bone-marrow-derived resident liver cells. TLR4 and the intestinal microbiota were not required for HCC initiation but for HCC promotion, mediating increased proliferation, expression of the hepatomitogen epiregulin, and prevention of apoptosis. Gut sterilization restricted to late stages of hepatocarcinogenesis reduced HCC, suggesting that the intestinal microbiota and TLR4 represent therapeutic targets for HCC prevention in advanced liver disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Moreover, HSC mediators besides RSPO3, such as HGF, but possibly also neurotrophin-319 or epiregulin60 may be involved in additional aspects of HSC–hepatocyte cross-talk and—together with ECs29,59—collaboratively control hepatocyte health and functions.”
From Hepatic stellate cells control liver zonation, size and functions via R-spondin 3 (2025) · cites this paper as [60]
In the citing paper
“These pro-inflammatory mediators not only promote the development of CLD but also set the stage for the development of HCC13–15.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [13]
In the citing paper
“However, a failing gut barrier and alterations of the gut microbiota in chronic liver disease (CLD) contribute to chronic inflammation and the progression of liver diseases12, and thereby increase risk for the development of hepatocellular carcinoma (HCC) as the final stage of the disease process 13–15.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [13]
In the citing paper
“Nonetheless, the bacterial microbiota has an important role in promoting HCC in the setting of liver fibrosis, as demonstrated by reduced HCC formation in TLR4-deficient, germ-free and antibiotic-treated mice in a diethylnitrosamine (DEN) plus CCl4 model of HCC13.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [13]
In the citing paper
“It has become apparent that the endogenous commensal microbiota provides hepatoprotective signals and that complete absence of the gut microbiota results in increased liver injury — probably owing to an absence of TLR4-mediated activation of anti-apoptotic NF-κB signalling — and a subsequent increase in liver fibrosis, as demonstrated in several models13,75,76.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [13]
In the citing paper
“Consistent with previous studies71–73, treatment with nonabsorbable antibiotics resulted in a strong reduction of fibrosis despite increased liver injury13.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [13]
In the citing paper
“Experiments in bone-marrow-chimeric mice demonstrated that TLR4 expressed on liver-resident cells (which include hepatocytes, HSCs and Kupffer cells) is responsible for promotion of fibrogenesis and hepatocarcinogenesis13.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [13]
In the citing paper
“Accordingly, epiregulin-deficient mice displayed reduced hepatocarcinogenesis when treated with DEN+CCl413.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [13]
In the citing paper
“Conversely, inhibition of TLR4 signalling suppresses liver inflammation, fibrosis and HCC formation in mice and rats13,14,73.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [13]
In the citing paper
“Accordingly, chronic infusion of low-dose LPS via osmotic pumps promotes HCC development in mice13.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [13]
In the citing paper
“As such, HCC development induced by the combination of DEN and CCl4 was attenuated in gut-sterilized and germ-free mice compared with their specific pathogen-free counterparts13.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [13]
In the citing paper
“Accordingly, expression of the apoptosis marker cleaved caspase 3 in TLR4-deficient and gut-sterilized mice is inversely correlated with the formation of tumours13.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [13]
In the citing paper
“In HSCs, TLR4 activation leads to an NF-κB-mediated upregulation of the hepatomitogen epiregulin13.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [13]
In the citing paper
“Continuous gut sterilization by a cocktail of oral antibiotics, consisting of ampicillin, neomycin, metronidazole and vancomycin, effectively reduced the number and size of HCC induced by DEN+CCl4 or DMBA+HFD in mice13,15.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [13]
In the citing paper
“Of note, rifaximin reduces HCC development in the DEN–CCl4 model of HCC, albeit less efficiently than the quadruple antibiotics cocktail described above13.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [13]
In the citing paper
“Of note, administration of antibiotics at late stages of carcinogenesis, when microscopic tumours already existed, was more efficient at reducing HCC in mice than administration at earlier stages13.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [13]
In the citing paper
“supported by a large number of studies preclinical studies showing a drastic (≈80%) reduction of HCC development in murine models13–15.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [13]
In the citing paper
“Several studies have shown a key role for the TLR4 pathway as a mediator of the disease-promoting effects of the gut–liver axis in CLD and hepatocarcinogenesis13,14,73.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
Inflammation and cancer: back to Virchow?
Balkwill, F., & Mantovani, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04046-0 · Cited by 7,746
Recognition of Commensal Microflora by Toll-Like Receptors Is Required for Intestinal Homeostasis
Rakoff-Nahoum, S., Paglino, J., Eslami-Varzaneh, F., Edberg, S., & Medzhitov, R. (2004) · Cell · doi:10.1016/j.cell.2004.07.002 · Cited by 4,251
Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling
Levental, K. R., Yu, H., Kass, L., Lakins, J. N., Egeblad, M., Erler, J. T., Fong, S. F. T., Csiszar, K., Giaccia, A., Weninger, W., et al. (2009) · Cell · doi:10.1016/j.cell.2009.10.027 · Cited by 4,101
Wang, C.-Y., Mayo, M., Korneluk, R., Goeddel, D., & Baldwin, A. (1998) · Science · doi:10.1126/science.281.5383.1680 · Cited by 2,950
Hepatocellular carcinoma in cirrhosis: Incidence and risk factors
Fattovich, G., Stroffolini, T., Zagni, I., & Donato, F. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.014 · Cited by 2,587
NF-κB functions as a tumour promoter in inflammation-associated cancer
Pikarsky, E., Porat, R. M., Stein, I., Abramovitch, R., Amit, S., Kasem, S., Gutkovich-Pyest, E., Urieli-Shoval, S., Galun, E., & Ben‐Neriah, Y. (2004) · Nature · doi:10.1038/nature02924 · Cited by 2,423
Schuppan, D., & Afdhal, N. H. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60383-9 · Cited by 2,089
Metabolic Syndrome and Altered Gut Microbiota in Mice Lacking Toll-Like Receptor 5
Vijay-Kumar, M., Aitken, J. D., Carvalho, F. A., Cullender, T. C., Mwangi, S., Srinivasan, S., Sitaraman, S. V., Knight, R., Ley, R. E., & Gewirtz, A. T. (2010) · Science · doi:10.1126/science.1179721 · Cited by 2,068
Gender Disparity in Liver Cancer Due to Sex Differences in MyD88-Dependent IL-6 Production
Naugler, W. E., Sakurai, T., Kim, S., Maeda, S., Kim, K., Elsharkawy, A. M., & Karin, M. (2007) · Science · doi:10.1126/science.1140485 · Cited by 1,955
Flagged first, then by citations
1 of the 50 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Toyoda, 1995, Epiregulin. A novel epidermal growth factor with mitogenic activity for rat primary hepatocytes, J. Biol. Chem., 270, 7495
Cited by
Sorted by citations
Items 901–999 of 999
Signal‐transducing innate receptors in tumor immunity
Hangai, S., Kimura, Y., Taniguchi, T., & Yanai, H. (2021) · Cancer Science · doi:10.1111/cas.14848 · Cited by 12
Nischalke, H. D., Fischer, J., Klüners, A., Matz‐Soja, M., Krämer, B., Langhans, B., Goeser, F., Soyka, M., Stickel, F., Spengler, U., et al. (2021) · Liver International · doi:10.1111/liv.14980 · Cited by 10
Dong, J., Li, Y., Xiao, H., Cui, M., & Fan, S. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0476 · Cited by 11
Hepatocellular Carcinoma: Understanding the Inflammatory Implications of the Microbiome
Khalyfa, A. A., Punatar, S., & Yarbrough, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158164 · Cited by 10
The clinical significance of lipopolysaccharide binding protein in hepatocellular carcinoma
Cai, Q., Jiang, J., Jin, R., Jin, G., & Jia, N. (2019) · Oncology Letters · doi:10.3892/ol.2019.11119 · Cited by 10
Antonopoulos, D., Balatsos, N. A. A., & Gourgoulianis, K. I. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.03.129 · Cited by 10
Negussie, A. H., Mikhail, A. S., Owen, J., Hong, N., Carlson, C. J., Tang, Y., Carrow, K. P., Mauda‐Havakuk, M., Lewis, A. L., Karanian, J. W., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-26094-1 · Cited by 9
Mechanism of inflammasomes in cancer and targeted therapies
Gu, Q., Zou, J., Zhou, Y. Y., & Deng, Q. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1133013 · Cited by 10
Sakamoto, S., Nagasaki, A., Shrestha, M., Shintani, T., Watanabe, A., Furusho, H., Chayama, K., Takata, T., & Miyauchi, M. (2023) · Scientific Reports · doi:10.1038/s41598-023-36553-y · Cited by 9
Respiratory Tract Oncobiome in Lung Carcinogenesis: Where Are We Now?
Czarnecka, K. H., Kordiak, J., Brzeziańska‐Lasota, E., & Pastuszak‐Lewandoska, D. (2023) · Cancers · doi:10.3390/cancers15204935 · Cited by 9
Acharya, S., & Thirunavukkarasu, C. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2902067 · Cited by 10
RNA m5C methylation: a potential modulator of innate immune pathways in hepatocellular carcinoma
Meng, S., Bai, J., Wang, H., Mei, L., Long, Z., & Shanfeng, L. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1362159 · Cited by 9
Genomic and transcriptomic analyses of chemical hepatocarcinogenesis aggravated by oncoprotein loss
Wang, X., Liu, Y., Zhang, S., Zhang, J., Lin, X., Liang, Y., Zong, M., Hanley, K. L., Lee, J., Karin, M., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000001037 · Cited by 9
Microbial Biomarkers in Liquid Biopsy for Cancer: An Overview and Future Directions
Luo, F., Wang, X., Ye, C., & Sun, H. (2024) · Cancer Control · doi:10.1177/10732748241292019 · Cited by 11
Big lessons from the little Akkermansia muciniphila in hepatocellular carcinoma
Yang, Y., & Shi, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1524563 · Cited by 9
Liu, Z., Ding, F., & Shen, X. (2021) · Molecular Genetics and Genomics · doi:10.1007/s00438-020-01759-6 · Cited by 9
Rôle du microbiote intestinal dans la réponse aux thérapies anti-tumorales
Vétizou, M., Daillère, R., & Zitvogel, L. (2017) · Biologie Aujourd hui · doi:10.1051/jbio/2017009 · Cited by 9
Is de novo hepatocellular carcinoma after transjugular intrahepatic portosystemic shunt increased?
Hüsing‐Kabar, A., Meister, T., Köhler, M., Domschke, W., Kabar, I., Wilms, C., Hild, B., Schmidt, H., & Heinzow, H. S. (2017) · United European Gastroenterology Journal · doi:10.1177/2050640617732886 · Cited by 9
Yamamoto, K., Honda, T., Yokoyama, S., Ma, L., Kato, A., Ito, T., Ishizu, Y., Kuzuya, T., Nakamura, M., Kawashima, H., et al. (2021) · Digestive and Liver Disease · doi:10.1016/j.dld.2021.02.013 · Cited by 10
Alterations in the Gut Microbiota of Tibetan Patients With Echinococcosis
Cao, D., Pang, M., Wu, D., Chen, G., Peng, X., Xu, K., & Fan, H. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.860909 · Cited by 9
da Fonseca, L. G., & Araújo, R. L. C. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i28.3573 · Cited by 9
Liakina, V., Strainienė, S., Stundienė, I., Maksimaityte, V., & Kazėnaitė, E. (2022) · World Journal of Hepatology · doi:10.4254/wjh.v14.i7.1277 · Cited by 11
Nutrition, Immunity, and Cancer
Ghaedi, E., Rezaei, N., & Mahmoudi, M. (2019) · Springer eBooks · doi:10.1007/978-3-030-16073-9_12 · Cited by 9
Improve gut microbiome: a new horizon of cancer therapy
Fukui, H. (2017) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn.2017.08.04 · Cited by 9
The gut microbiome, antitumor immunity, and liver cancer
Mima, K., & Baba, H. (2019) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn.2018.11.09 · Cited by 9
Ye, C., Zhang, B., Lin, Y., Han, F., Shi, H., Dong, C., & Zhou, W. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1523863 · Cited by 9
Severe steatosis and mild colitis are important for the early occurrence of hepatocellular carcinoma
Sato, T., Tsuchiya, A., Owaki, T., Kumagai, M., Motegi, S., Iwasawa, T., Nojiri, S., Ogawa, M., Takeuchi, S., Watanabe, Y., et al. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.05.097 · Cited by 8
Kwan, S., Slayden, A. N., Coronado, A. R., Marquez, R. C., Chen, H., Wei, P., Savage, M. I., Vornik, L. A., Fox, J. T., Sei, S., et al. (2022) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-22-0332 · Cited by 8
Golonka, R. M., Yeoh, B. S., Saha, P., Gohara, A. F., Tummala, R., Stepkowski, S. M., Tiwari, A. K., Joe, B., Gonzalez, F. J., Gewirtz, A. T., et al. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000166 · Cited by 8
Gut microbiome-mediated monocytes promote liver metastasis
Zhang, W., Ling, J., Xu, B., Wang, J., Chen, Z., & Li, G. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.111877 · Cited by 9
The intrahepatic bacterial metataxonomic signature of patients with hepatocellular carcinoma
Li, J., Zhai, X., Chen, C., Zhang, R., Huang, X., & Liu, Y. (2024) · Scientific Reports · doi:10.1038/s41598-024-80246-z · Cited by 8
GLP-1 and IL-6 regulates obesity in the gut and brain
Yang, K., Wu, Y., He, Y., Dai, J.-X., Luo, Y.-L., Xie, J.-H., & Ding, W. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.123339 · Cited by 8
Animal models for hepatocellular carcinoma arising from alcoholic and metabolic liver diseases
Liu, K., Chen, J., & McCaughan, G. W. (2020) · Hepatoma Research · doi:10.20517/2394-5079.2019.39 · Cited by 8
Microbiome and gastrointestinal malignancies
Sayed, I. M., Ramadan, H. K., El‐Mokhtar, M. A., & Abdel-Wahid, L. (2021) · Current Opinion in Physiology · doi:10.1016/j.cophys.2021.06.005 · Cited by 8
Zhang, T., Wang, J., Yao, Z., Ni, L., Zhao, Y., Wei, S., & Chen, Z. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.914684 · Cited by 8
Vascular and lymphatic regulation of gastrointestinal function and disease risk
Cifarelli, V., Peche, V. S., & Abumrad, N. A. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2022.159207 · Cited by 9
Butters, C. T., Thursky, K., Hanna, D. T., Cole, T. S., Davidson, A. J., Buttery, J. P., & Haeusler, G. M. (2023) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2023.2171987 · Cited by 8
Cao, Y., Zhang, L., Xiong, F., Guo, X., Kan, X., Song, S., Liang, B., Liang, B., Li, Y., & Zheng, C. (2023) · Future Microbiology · doi:10.2217/fmb-2022-0234 · Cited by 9
Ezzat, W. M., & Amr, K. S. (2016) · World Journal of Hepatology · doi:10.4254/wjh.v8.i30.1251 · Cited by 8
Innovative Therapy, Monoclonal Antibodies and Beyond
Nicola, M. D., Apétoh, L., Bellone, M., Colombo, M. P., Dotti, G., Ferrone, S., Muscolini, M., Hiscott, J. B., Anichini, A., Pupa, S. M., et al. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.10.002 · Cited by 8
Predictive Values of Colon Microbiota in the Treatment Response to Colorectal Cancer
Ros, J. G., Ramos-Arenas, V., & Conesa‐Zamora, P. (2020) · Pharmacogenomics · doi:10.2217/pgs-2020-0044 · Cited by 9
The gut takes a toll on liver cancer
Alderton, G. K. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3283 · Cited by 8
Kim, H.-R., Seo, C.-W., & Kim, J. (2023) · Osong Public Health and Research Perspectives · doi:10.24171/j.phrp.2023.0229 · Cited by 7
Qian, W., He, L., Fu, C., Zeng, T., Wang, H., & Li, H. (2025) · Exploration of Digestive Diseases · doi:10.37349/edd.2025.100579 · Cited by 7
Profiling of the tumor-associated microbiome in patients with hepatocellular carcinoma
Schulz, C., Vilchez‐Vargas, R., Öcal, E., Koch, N., Puhr‐Westerheide, D., Burnell, L. F., Hirner-Eppeneder, H., Benckert, J., Pech, M., Reimer, P., et al. (2025) · Gut Pathogens · doi:10.1186/s13099-025-00727-y · Cited by 7
Li, Q., & Liu, Y. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1701101 · Cited by 7
Small Animals Gut Microbiome and Its Relationship with Cancer
Ferrarias, T. M., & Santos, A. A. F. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.95780 · Cited by 7
Intratumoral microbiota: an emerging force in diagnosing and treating hepatocellular carcinoma
Liu, H., Zhang, J., Rao, Y., Jin, S., Zhang, C., & Bai, D. (2024) · Medical Oncology · doi:10.1007/s12032-024-02545-9 · Cited by 9
Progress in the Study of Intratumoral Microorganisms in Hepatocellular Carcinoma
Song, Y., Tian, S., Li, Z., Miao, J., Wu, M., Xu, T., Wu, X., Qiao, J., Zhang, X., Zhao, H., et al. (2025) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s496964 · Cited by 7
Markowitz, G. J., Michelotti, G. A., Diehl, A. M., & Wang, X.-F. (2015) · 中国科学通报：英文版 · doi:10.1007/s11434-015-0772-5 · Cited by 7
Hepatocellular Cancer and Gut Microbiome: Time to Untie Gordian’s Knot
Aygün, C., & Tozun, N. A. (2021) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-021-00736-5 · Cited by 7
Watahiki, T., Okada, K., Miura, I., To, K., Tanaka, S., Warabi, E., Kanno, N. I., Yamagata, K., Gotoh, N., Suzuki, H., et al. (2022) · Antioxidants · doi:10.3390/antiox11101939 · Cited by 7
Deciphering the tumour immune microenvironment of hepatocellular carcinoma
Liu, S., Jia, M., & Dai, R. (2023) · Scandinavian Journal of Immunology · doi:10.1111/sji.13327 · Cited by 7
Oral Microbiota Associated with Oral and Gastroenteric Cancer
Robayo, D. A. G., Flores-Hernández, R., Erira, H. A. T., Kandaurova, L., Juarez, C. L., Juárez, V., & Arregui, A. C. (2020) · The Open Microbiology Journal · doi:10.2174/1874285802014010001 · Cited by 7
Donati, B., Ferrari, A., Ruffini, A., Manzotti, G., Fragliasso, V., Merli, F., Zanelli, M., Valli, R., Luminari, S., & Ciarrocchi, A. (2020) · Hematological Oncology · doi:10.1002/hon.2827 · Cited by 7
The day will come to treat HCC in a drugstore?
Miura, K. (2017) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn.2017.07.09 · Cited by 7
Cheng, M., Zheng, X., Wei, J., & Liu, M. (2023) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2023.12285 · Cited by 6
Lu, W., Aihaiti, A., Abudukeranmu, P., Liu, Y., & Gao, H. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05320-6 · Cited by 8
Regulating gut microbiota with nanomaterials for cancer immunotherapy
Sha, T., Tang, Y., Hu, X., Zhou, H., & Rao, L. (2025) · Interdisciplinary medicine · doi:10.1002/inmd.20240103 · Cited by 6
Li, T., & Jing, W. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1565778 · Cited by 7
Sun, X. L., Zhou, Z., Chi, X., Cheng, D., Zhang, Y., Xu, Y., Hao, Y., Duan, Y., Li, W., Zhao, Y., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1674838 · Cited by 6
The Gut Microbiome Role in Multiple Myeloma: Emerging Insights and Therapeutic Opportunities
George, M. Y., Gamal, N. K., Mansour, D. E., Famurewa, A. C., Bose, D., Messiha, P. A., & Cerchione, C. (2025) · Hematology Reports · doi:10.3390/hematolrep17060056 · Cited by 6
Intratumoral Microbiome: Impact on Cancer Progression and Cellular Immunotherapy
Leonov, G. E., Starodubova, A. V., Makhnach, O. V., Goldshtein, D. V., & Salikhova, D. I. (2025) · Cancers · doi:10.3390/cancers18010100 · Cited by 7
The gut as a central hub for multi-organ crosstalk in aging
Zhang, X., Li, R., Gao, Y., Zhang, W., Ni, T., & Liu, Y. (2026) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-026-06129-w · Cited by 7
Sha, J., Zhang, R., Fan, J., Gu, Y., Pan, Y., Han, J., Xu, X., Ren, S., & Gu, J. (2022) · Cancers · doi:10.3390/cancers14051333 · Cited by 6
TLR4 inhibited autophagy by modulating PI3K/AKT/mTOR signaling pathway in Gastric cancer cell lines
Zhang, Q., Dan, J., Meng, S., Li, Y., & Li, J. (2023) · Gene · doi:10.1016/j.gene.2023.147520 · Cited by 6
Bi, Y., Zhang, L., Song, Y., Sun, L., Mulholland, M. W., Yin, Y., & Zhang, W. (2023) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2023.05.016 · Cited by 6
Kubo, T., Nishimura, N., Kaji, K., Tomooka, F., Shibamoto, A., Iwai, S., Suzuki, J., Kawaratani, H., Namisaki, T., Akahane, T., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084405 · Cited by 6
Wu, B., Quan, C., He, Y., Matsika, J., Huang, J., Liu, B., & Chen, J. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2371543 · Cited by 6
Thomasclavelia ramosa and alcohol-related hepatocellular carcinoma: a microbial culturomics study
Wasfy, R. M., Abdoulaye, A. I., Borentain, P., Mbaye, B., Alou, M. T., Caputo, A., Andrieu, C., Mottola, G., Levasseur, A., Million, M., et al. (2025) · Gut Pathogens · doi:10.1186/s13099-025-00703-6 · Cited by 6
The crosstalk between gut microbiota and microbiota-derived metabolites in hepatocellular carcinoma
Yoon, S. J., Han, S. K., Kim, T. S., Suk, K. T., Choi, D. H., Kim, Y. D., Kim, M. Y., Cheon, G. J., Baik, S. K., & Kim, D. J. (2025) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2025.2501590 · Cited by 7
Bouzas, A., Giménez‐Bastida, J. A., García-Tejedor, A., Haros, C. M., de Cedrón, M. G., de Molina, A. R., & Laparra, J. M. (2021) · Biomedicines · doi:10.3390/biomedicines9111633 · Cited by 6
Ashfaq, I., Sheikh, N., Fatima, N., & Tayyeb, A. (2022) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2022.103348 · Cited by 6
RETRACTED ARTICLE: Anti-cancer activity of human gastrointestinal bacteria
Quazi, S. (2022) · Medical Oncology · doi:10.1007/s12032-022-01771-3 · Cited by 12
RetractedLiu, J., Li, Q., & Tan, R. (2022) · Food Science and Technology · doi:10.1590/fst.25022 · Cited by 6
Cramer, T. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101736 · Cited by 6
The Role of the Microbiome in Inflammation and Carcinogenesis
Jabłońska‐Trypuć, A. (2023) · Frontiers in Bioscience-Elite · doi:10.31083/j.fbe1504028 · Cited by 6
CYLD and HCC: When Being Too Sensitive to Your Dirty Neighbors Results in Self-Destruction
Font-Burgada, J., Seki, E., & Karin, M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.05.034 · Cited by 6
Gut Microbiota and Inflammatory Disorders
Krishna, V., Kumar, N., & Banerjee, S. (2021) · Current Drug Targets · doi:10.2174/1389450122666210623125603 · Cited by 6
Experimental Hepatocarcinogenesis
Caviglia, J. M., & Schwabe, R. F. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-386456-7.04212-x · Cited by 6
Self-citationHepatic Stellate Cells and Liver Cancer
Dapito, D. H., & Schwabe, R. F. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800134-9.00009-9 · Cited by 5
Self-citationObesity and Hepatocellular Carcinoma
Xu, W., & Yu, J. Q. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804274-8.00020-5 · Cited by 6
Hepatocellular Carcinoma in Obesity: Finding a Needle in the Haystack?
Baffy, G. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-8684-7_6 · Cited by 7
The intestinal microbiota and hepatocellular carcinoma
Effenberger, M., & Tilg, H. (2020) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-020-00597-x · Cited by 6
Adisa, R. A., & Sulaimon, L. A. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.105473 · Cited by 6
Anti-cancer Activity of Human Gastrointestinal BacteriaPreprint
Quazi, S. (2021) · Preprints.org · doi:10.20944/preprints202112.0433.v1 · Cited by 6
Sleep disorders in hepatocellular carcinoma
Qian, J., Ruan, M., Wang, Z., Dong, W., Jia, J.-H., Feng, X.-C., & Liu, H. (2025) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v17.i10.110503 · Cited by 5
Modulating Bacteroides to boost anti-PD-1 immunotherapy in HCC
Qi, X., Yang, M. J., Liu, X., Ma, L., Kaifi, J. T., Ericsson, A. C., Kimchi, E. T., Staveley-O’Carroll, K. F., & Li, G. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013755 · Cited by 5
Probiotics—A Promising Novel Therapeutic Approach in the Management of Chronic Liver Diseases
Ramachandran, G., & Pottakkat, B. (2024) · Journal of Medicinal Food · doi:10.1089/jmf.2023.k.0129 · Cited by 5
Zou, R., Hao, Y., Qi, C., Peng, X., Huang, Z., Li, D., & Wang, Y. (2024) · Journal of drug targeting · doi:10.1080/1061186x.2024.2344495 · Cited by 5
Hu, B., Yang, Y., Yao, J., Lin, G., He, Q., Bo, Z., Zhang, Z., Li, A., Wang, Y., Chen, G., et al. (2024) · Cancer Medicine · doi:10.1002/cam4.70454 · Cited by 5
Microbial characteristics of gut microbiome dysbiosis in patients with chronic liver disease
Ma, C., Yang, J., Fu, X., Luo, J., Liu, P., Zeng, X.-L., Li, X., Zhang, S.-L., & Zheng, S. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i5.106124 · Cited by 5
Debré, P., & Gall, J. L. (2014) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)31175-6 · Cited by 6
Mustafa, K., Yu, S., Mohamed, H., Qi, T., Xiao, H., ciali, S., Wu, Y., Naz, T., Nosheen, S., Bai, X., et al. (2021) · Applied Sciences · doi:10.3390/app112411810 · Cited by 5
Zhang, J., Zao, X., Zhang, J., Guo, Z., Jin, Q., Chen, G., Gan, D., Du, H., & Ye, Y. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109627 · Cited by 5
Forging the microbiome to help us live long and prosper
Rock, R. R., & Turnbaugh, P. J. (2023) · PLoS Biology · doi:10.1371/journal.pbio.3002087 · Cited by 5
Zhu, Y., Mei, Y., Baby, N., Teo, H. Y., Hanafi, Z. B., Salleh, S. N. M., Sajikumar, S., & Liu, H. (2023) · Communications Biology · doi:10.1038/s42003-023-05036-1 · Cited by 5
Hoshino, K., Nakazawa, S., Yokobori, T., Hagiwara, K., Ishii, N., Tsukagoshi, M., Igarashi, T., Araki, K., Harimoto, N., Tokunaga, F., et al. (2024) · Scientific Reports · doi:10.1038/s41598-023-50594-3 · Cited by 6
Modelling hepatocellular carcinoma microenvironment phenotype to evaluate drug efficacy
Cherradi, S., Roux, S., Dupuy, M., Tabone‐Eglinger, S., Tuaillon, É., Ziol, M., Assénat, E., & Duong, H. T. (2025) · Scientific Reports · doi:10.1038/s41598-024-84304-4 · Cited by 5
Metadata
- Authors
- Dapito, D. H., Mencin, A., Gwak, G.-Y., Pradere, J.-P., Jang, M.-K., Mederacke, I., Caviglia, J. M., Khiabanian, H., Adeyemi, A., Bataller, R., Lefkowitch, J. H., Bower, M., Friedman, R., Sartor, R. B., Rabadan, R., & Schwabe, R. F.
- Affiliations
- Columbia University (US)
- Samsung Medical Center (KR)
- Hospital Clínic de Barcelona (ES)
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Schwabe, Robert F.
- ORCID
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2012-04
- Volume
- 21
- Issue
- 4
- Pages
- 504-516
- ISSN
- 1535-6108 (ISSN-L)
- PMC
- PMC3332000
- OpenAlex
- W2085153086
- Cited by
- 1,346
- References
- 50
- Citations by year
- 2026: 63 · 2025: 103 · 2024: 106 · 2023: 111 · 2022: 149 · 2021: 133 · 2020: 129 · 2019: 104 · 2018: 93 · 2017: 94 · 2016: 79 · 2015: 64 · 2014: 48 · 2013: 51 · 2012: 16
- FWCI
- 36.26
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 472 d)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- Cancer Cell (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion, cc-by)
- UNC Libraries
- Funders
- National Institutes of Health (1F31 DK091980-01, P40RR018603, R01AA020211, R01DK076920, U54CA163111)
- Topics
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Keywords
- hepatocellular carcinoma, gut microbiota, TLR4, gut-liver axis, chronic liver injury, hepatocarcinogenesis, bacterial translocation, epiregulin, apoptosis, HCC prevention, liver fibrosis, liver inflammation
- MeSH terms
- Animals, Epidermal Growth Factor, Humans, Intestines, Liver Diseases, Liver Neoplasms, Experimental, Mice, Inbred C57BL, Tumor Cells, Cultured, Apoptosis, Bacterial Translocation, Cell Proliferation, Toll-Like Receptor 4, Mice, Epiregulin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
